Evidence map›Paper›PMID 32874137›Full record

ArticleCost effectiveness and resource allocation : C/E2020

Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling-an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine.

Zoltán Vokó, István Bitter, Beatrix Mersich, János Réthelyi, Anett Molnár, János G Pitter, Árpád Götze, Margit Horváth, Kristóf Kóczián, Laura Fonticoli and 2 more

Abstract read
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zoltán VokóCenter for Health Technology Assessment, Semmelweis University, Üllői út 25, 1091 Budapest, Hungary.ORCID 0000-0002-1004-1848
István BitterDepartment of Psychiatry and Psychotherapy, Semmelweis University, Balassa utca 6, 1083 Budapest, Hungary.
Beatrix MersichDepartment of Psychiatry and Psychotherapy, Semmelweis University, Balassa utca 6, 1083 Budapest, Hungary.
János RéthelyiDepartment of Psychiatry and Psychotherapy, Semmelweis University, Balassa utca 6, 1083 Budapest, Hungary.
Anett MolnárSyreon Research Institute, Mexikói út 65/A, 1142 Budapest, Hungary.
János G PitterSyreon Research Institute, Mexikói út 65/A, 1142 Budapest, Hungary.
Árpád GötzeRichter Gedeon Plc, Gyömrői út 19-21, 1103 Budapest, Hungary.
Margit HorváthRichter Gedeon Plc, Gyömrői út 19-21, 1103 Budapest, Hungary.
Kristóf KócziánRichter Gedeon Plc, Gyömrői út 19-21, 1103 Budapest, Hungary.
Laura FonticoliRecordati S.P.A, Via Matteo Civitali 1, 20148 Milano, MI Italy.
Filippo LelliRecordati S.P.A, Via Matteo Civitali 1, 20148 Milano, MI Italy.
Bertalan NémethSyreon Research Institute, Mexikói út 65/A, 1142 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhen patient health state transition evidence is missing from clinical literature, analysts are inclined to make simple assumptions to complete the transition matrices within a health economic model. Our aim was to provide a solution for estimating transition matrices by the Bayesian statistical method within a health economic model when empirical evidence is lacking.

methodsWe used a previously published cost-effectiveness analysis of the use of cariprazine compared to that of risperidone in patients with predominantly negative symptoms of schizophrenia. We generated the treatment-specific state transition probability matrices in three different ways: (1) based only on the observed clinical trial data; (2) based on Bayesian estimation where prior transition probabilities came from experts' opinions; and (3) based on Bayesian estimation with vague prior transition probabilities (i.e., assigning equal prior probabilities to the missing transitions from one state to the others). For the second approach, we elicited Dirichlet prior distributions by three clinical experts. We compared the transition probability matrices and the incremental quality-adjusted life years (QALYs) across the three approaches.

resultsThe estimates of the prior transition probabilities from the experts were feasible to obtain and showed considerable consistency with the clinical trial data. As expected, the estimated health benefit of the treatments was different when only the clinical trial data were considered (QALY difference 0.0260), its combination with the experts' beliefs were used in the economic model (QALY difference 0.0253), and when vague prior distributions were used (QALY difference 0.0243).

conclusionsImputing zeros to missing transition probabilities in Markov models might be untenable from the clinical perspective and may result in inappropriate estimates. Bayesian statistics provides an appropriate framework for imputing missing values without making overly simple assumptions. Informative priors based on expert opinions might be more appropriate than vague priors.

Indexed as

Bayesian statisticsMarkov modelSchizophreniaTransition probabilities

Identifiers

PMID32874137
PMCPMC7457290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.